Answers are grounded in this paper and cite their sources.
Analytical development study demonstrates comprehensive determination of all proteinogenic amino acid enantiomers in human plasma and urine, highlighting biomarker profiling capabilities.
An online three-dimensional (3D) HPLC system was designed/developed for the comprehensive determination of all proteinogenic amino acid enantiomers, including allo-isoleucine, allo-threonine (aThr), and 3 cystine (Cys) stereoisomers (dd/dl/ll-forms), in real-world samples with one injection. d-Amino acids are candidates for physiologically active molecules and/or biomarkers, and the simultaneous determination of all the proteinogenic chiral amino acids is expected. However, the amounts of d-amino acids in biological samples are usually much lower than those of other intrinsic substances, including l-amino acids and peptides; thus, the analytical method for the determination of d-amino acids requires high selectivity. In the present study, a reversed-phase column (Singularity RP18) and a mixed-mode column (Singularity MX-103) were utilized to separate all of the proteinogenic amino acids as their scalemic mixtures, and a Pirkle-type enantioselective column (Singularity CSP-001S) was used for the chiral separations. By using the 3D-HPLC system, all of the proteinogenic amino acids and allo-forms were enantioselectively separated, and the determination of these chiral amino acids in human plasma and urine was carried out without interference from intrinsic substances. As a result, 5 d-amino acids (alanine, asparagine, aThr, proline, and serine) were clearly determined in human plasma, and the peaks of 19 d-amino acids (i.e., all the target d-amino acids except for d-isoleucine and dd-Cys) and dl-Cys were observed in human urine. The present 3D-HPLC system achieved the simultaneous and selective determination of all proteinogenic amino acid enantiomers, including 2 allo-forms and 3 Cys stereoisomers, in biological matrices for the first time, to the best of our knowledge.
No takes yet. Share an insight, caveat, or question.
Nagata et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: